Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Morepen Laboratories announced the launch of four new products—Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month continuing.
This strategic expansion reinforces Morepen's commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high quality medicines. Importantly, all APIs used in these products are manufactured in-house by Morepen at its world-class, USFDA-approved plants, ensuring consistent quality and supply chain control.
Morepen Laboratories today announced a bold expansion plan aimed at deepening its connect with doctors, patients, pharmacies, and healthcare professionals across the country. As part of this strategic initiative, the company will add more than 1,000 professionals to its salesforce over the next three years, with over 200 team members expected to join in FY26 alone.
'This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domes c finished dosage market,' said Sushil Suri, Chairman and Managing Director of Morepen Laboratories. 'With the leadership in our high value APIs, this significant increase in our salesforce and enhanced reach to doctors, pharmacies, and patients, we are se ng the stage for getting a bigger pie in the Indian pharmaceutical market valued at ₹2.38 lakh crore, yielding higher gross margins and be er returns for stakeholders in the long run.”
To achieve this, the company plans aggressive expansion of its medical representative network and deeper market penetration across both urban and rural India. A key driver of this growth will be its pipeline of competitively priced new products already in production.
The Indian pharmaceutical market, projected to reach $130 billion by 2030 with an annual growth rate of 8.2%, positions India as the emerging pharmacy of the world—offering a strong runway for players like Morepen.
Morepen Laboratories' operations span APIs, medical devices, and finished formulations. The company is a global exporter of six major APIs, including Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine. In the medical devices segment, Morepen has installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, supporting its expansion into tier-2 and tier-3 cities.
The company's consolidated net profit fell 16.6% to Rs 26.69 crore while revenue from operations rose 1.9% to Rs 452.78 crore in Q3 December 2024 over Q3 December 2023.
Morepen Laboratories has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for its Loratadine (anti-allergy API). This marks a significant milestone in Morepen's strategic entry into one of the world's largest pharmaceutical markets.
Morepen commands an over 80% market share in the US generics market for Loratadine, making it the undisputed leader in its category. The company has been exporting to the US market for over 25 years, its API exports alone are valued at Rs.650 crores. This approval further solidifies Morepen's position as the dominant global manufacturer of Loratadine, a widely prescribed second-generation antihistamine and anti-allergy drug used to treat allergic symptoms such as hay fever and chronic urticaria. With this development, Morepen is poised to capture a significant share of the Chinese market while reinforcing its standing in the global pharmaceutical landscape.
This approval marks a significant milestone for Morepen as it strategically enters one of the world’s largest pharmaceutical markets, China.
Morepen holds an over 80% market share in the U.S. generics market for Loratadine, making it the undisputed leader in this category. The company has been exporting to the U.S. for over 25 years, with API exports alone valued at approximately Rs 650 crore.
This approval further solidifies Morepen’s position as the dominant global manufacturer of Loratadine, a widely prescribed second-generation antihistamine and anti-allergy drug used to treat allergic symptoms such as hay fever and chronic urticaria.
With this development, Morepen is poised to capture a significant share of the Chinese market while reinforcing its standing in the global pharmaceutical landscape.
Kushal Suri, director of sales & marketing at Morepen Laboratories, said, “The approval by China’s NMPA is a testament to Morepen’s unwavering commitment to quality, regulatory excellence, and global market expansion.”
Further, he added, “China represents a vast growth opportunity, and this milestone will allow us to meet the increasing demand for high-quality antihistamine and anti-allergy APIs while reinforcing our leadership in global healthcare.”
Morepen Laboratories is a leading player in the pharmaceutical and healthcare industry. With a strong presence in APIs, medical devices, and finished formulations, Morepen has consistently demonstrated innovation and market leadership. The company is a global leader in exporting 6 key API products, including Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine. In the medical devices segment, Morepen has made remarkable strides in Point of Care (POC) diagnostics, having installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, driving expansion into tier-2 and tier-3 cities.
The company’s consolidated net profit fell 16.6% to Rs 26.69 crore in Q3 FY25 as against Rs 31.99 crore posted in Q3 FY24. However, revenue from operations rose 1.9% YoY to Rs 452.78 crore in the quarter ended 31 December 2024.